Phoenix Biotech Sponsor, Llc - Oct 8, 2021 Form 4 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (PBAX)

Role
10%+ Owner
Signature
/s/ Chris Ehrlich, Manager
Stock symbol
PBAX
Transactions as of
Oct 8, 2021
Transactions value $
$367,330
Form type
4
Date filed
10/12/2021, 07:41 PM
Previous filing
Oct 5, 2021
Next filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBAX Class A common stock Other $367K +36.7K +5.54% $10.00 700K Oct 8, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBAX Class B Common Stock Other -82.9K -1.77% 4.6M Oct 8, 2021 Class A Common Stock 82.9K Direct F3, F4
transaction PBAX Warrants Other $0 +18.4K +5.54% $0.00 350K Oct 8, 2021 Class A Common Stock 18.4K $11.50 Direct F1, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition by reporting person in connection with the partial exercise of the underwriters' over-allotment option.
F2 These shares underlie the same number of units of the issuer held by the reporting person.
F3 The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date.
F4 Forfeiture and cancellation of shares of Class B common stock for no consideration because the underwriters' over-allotment option was not exercised in full.
F5 The warrants will become exercisable at the later of 30 days after the consummation of the issuer's initial business combination or 12 months from the completion of the issuer's initial public offering.
F6 The warrants will expire five years after the consummation of the issuer's initial business combination or earlier upon redemption of all of the issuer's outstanding Class A common shares or the issuer's liquidation.